´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2021 Ãá°èÇмú´ëȸ : 2021-04-10±³À°ÀÏÀÚ : 2021-04-10
±³À°Àå¼Ò : ÀÓÇǸ®¾óÆÓ¸®½º È£ÅÚ ¼¿ï
±³À°ÁÖÁ¦ :
´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2021 Ãá°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÆÄŲ½¼º´¹×ÀÌ»ó¿îµ¿ÁúȯÇÐȸ
´ã´çÀÚ : ±è½Ã¿ø
¿¬¶ôó : 02-6395-2876
À̸ÞÀÏ :
movement@kmds.or.kr ±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í Á¤È¸¿ø 30,000¿ø / ÁØȸ¿ø 20,000¿ø / ºñȸ¿ø 40,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 09:00~09:40 alpha-synuclein pathology in the skin Charles Adler(Mayo Clinic, USA)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 09:40~10:10 Neuromodulation in PD and neurodegnerative diseases ¿ÀÀÀ¼®(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 10:10~10:40 Recent clinical trials in PD: positive and negative õ»ó¸í(µ¿¾ÆÀÇ´ë)
ÈÞ½Ä 04-10 10:40~10:50 ÈÞ½Ä ()
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 10:50~11:20 The link between two pathogenic mechanisms: synucleinopathy and inflammation in PD ±è¿µÀº(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 11:20~11:50 GBA, lysosome and PD Ç㿵Àº(Â÷ÀÇ°úÇдë)
ÈÞ½Ä 04-10 11:50~12:00 ÈÞ½Ä ()
±âŸ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 12:00~13:00 ÃÑȸ ¹× Á¡½É½Ä»ç ±Çµµ¿µ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 13:00~13:30 Autonomic dysfunction in PD: pathophysiology and management ¿ÀÀ±»ó(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 13:30~14:00 Update in medical treatment for PD ÀÌÁöÀº(±¹¹Î°Ç°º¸Çè°ø´ÜÀϻ꺴¿ø)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 14:00~14:30 Iron-sensitive MRI in parkinsonism ÀÌÀçÇõ(ºÎ»êÀÇ´ë)
ÈÞ½Ä 04-10 14:30~14:40 ÈÞ½Ä ()
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 14:40~15:10 iRBD and syncleinopathy ÀÌÁö¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 15:10~15:40 Rare genetic disorders with parkinsonism Àå¿ì¿µ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-10 ¸Þ±×·¹Ã÷¾Ë¸®¿ÀÃ÷ 15:40~16:20 Heterogeneity of PD Robert de Bie(Amsterdam UMC)